{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:03:17Z","timestamp":1793120597385,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Few live attenuated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are in pre-clinical or clinical development. We seek to attenuate SARS-CoV-2 (isolate WA1\/2020) by removing the polybasic insert within the spike protein and the open reading frames (ORFs) 6\u20138, and by introducing mutations that abolish non-structural protein 1 (Nsp1)-mediated toxicity. The derived virus (WA1-\u0394PRRA-\u0394ORF6-8-Nsp1\n                    <jats:sup>K164A\/H165A<\/jats:sup>\n                    ) replicates to 100- to 1000-fold-lower titers than the ancestral virus and induces little lung pathology in both K18-human ACE2 (hACE2) transgenic mice and Syrian hamsters. Immunofluorescence and transcriptomic analyses of infected hamsters confirm that three-pronged genetic modifications attenuate the proinflammatory pathways more than the removal of the polybasic cleavage site alone. Finally, intranasal administration of just 100 PFU of the WA1-\u0394PRRA-\u0394ORF6-8-Nsp1\n                    <jats:sup>K164A\/H165A<\/jats:sup>\n                    elicits robust antibody responses in Syrian hamsters and protects against SARS-CoV-2-induced weight loss and pneumonia. As a proof-of-concept study, we demonstrate that live but sufficiently attenuated SARS-CoV-2 vaccines may be attainable by rational design.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-34571-4","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T08:03:04Z","timestamp":1668067384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-6041","authenticated-orcid":false,"given":"Shufeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Stauft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-3928","authenticated-orcid":false,"given":"Prabhuanand","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4134-9490","authenticated-orcid":false,"given":"Felice","family":"D\u2019Agnillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Kai","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-887X","authenticated-orcid":false,"given":"Christopher Z.","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement A.","family":"Meseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyntia L.","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Starost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry P.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8983-1721","authenticated-orcid":false,"given":"Tony T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"34571_CR1","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","volume":"398","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet 398, 2173\u20132184 (2021).","journal-title":"Lancet"},{"key":"34571_CR2","doi-asserted-by":"publisher","unstructured":"Mok, C. K. P. et al. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology https:\/\/doi.org\/10.1111\/resp.14191 (2021).","DOI":"10.1111\/resp.14191"},{"key":"34571_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med"},{"key":"34571_CR4","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 398, 1407\u20131416 (2021).","journal-title":"Lancet"},{"key":"34571_CR5","doi-asserted-by":"publisher","unstructured":"Abu-Raddad, L. J. et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2200797 (2022).","DOI":"10.1056\/NEJMoa2200797"},{"key":"34571_CR6","doi-asserted-by":"publisher","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2119451 (2022).","DOI":"10.1056\/NEJMoa2119451"},{"key":"34571_CR7","doi-asserted-by":"publisher","unstructured":"Chenchula, S., Karunakaran, P., Sharma, S. & Chavan, M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.27697 (2022).","DOI":"10.1002\/jmv.27697"},{"key":"34571_CR8","doi-asserted-by":"publisher","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01753-y (2022).","DOI":"10.1038\/s41591-022-01753-y"},{"key":"34571_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.imlet.2022.02.002","volume":"243","author":"SO Minka","year":"2022","unstructured":"Minka, S. O. & Minka, F. H. A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant. Immunol. Lett. 243, 38\u201343 (2022).","journal-title":"Immunol. Lett."},{"key":"34571_CR10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"34571_CR11","doi-asserted-by":"publisher","first-page":"112527","DOI":"10.1016\/j.biopha.2021.112527","volume":"146","author":"MR Zinatizadeh","year":"2022","unstructured":"Zinatizadeh, M. R. et al. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. Biomed. Pharmacother. 146, 112527 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"34571_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527 (2020).","journal-title":"Nature"},{"key":"34571_CR13","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc. Natl Acad. Sci. USA 118, https:\/\/doi.org\/10.1073\/pnas.2102775118 (2021).","DOI":"10.1073\/pnas.2102775118"},{"key":"34571_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23166-0","volume":"12","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1\/S2 junction of the spike protein. Nat. Commun. 12, 2790 (2021).","journal-title":"Nat. Commun."},{"key":"34571_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/22221751.2020.1756700","volume":"9","author":"SY Lau","year":"2020","unstructured":"Lau, S. Y. et al. Attenuated SARS-CoV-2 variants with deletions at the S1\/S2 junction. Emerg. Microbes Infect. 9, 837\u2013842 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"34571_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","volume":"591","author":"BA Johnson","year":"2021","unstructured":"Johnson, B. A. et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591, 293\u2013299 (2021).","journal-title":"Nature"},{"key":"34571_CR17","doi-asserted-by":"publisher","first-page":"e0141521","DOI":"10.1128\/mBio.01415-21","volume":"12","author":"M Sasaki","year":"2021","unstructured":"Sasaki, M. et al. SARS-CoV-2 bearing a mutation at the S1\/S2 cleavage site exhibits attenuated virulence and confers protective immunity. mBio 12, e0141521 (2021).","journal-title":"mBio"},{"key":"34571_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.it.2021.10.009","volume":"42","author":"N Jouvenet","year":"2021","unstructured":"Jouvenet, N., Goujon, C. & Banerjee, A. Clash of the titans: interferons and SARS-CoV-2. Trends Immunol. 42, 1069\u20131072 (2021).","journal-title":"Trends Immunol."},{"key":"34571_CR19","doi-asserted-by":"publisher","first-page":"108234","DOI":"10.1016\/j.celrep.2020.108234","volume":"33","author":"H Xia","year":"2020","unstructured":"Xia, H. et al. Evasion of Type I Interferon by SARS-CoV-2. Cell Rep. 33, 108234 (2020).","journal-title":"Cell Rep."},{"key":"34571_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-021-03610-3","volume":"594","author":"Y Finkel","year":"2021","unstructured":"Finkel, Y. et al. SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. Nature 594, 240\u2013245 (2021).","journal-title":"Nature"},{"key":"34571_CR21","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/nsmb.1680","volume":"16","author":"W Kamitani","year":"2009","unstructured":"Kamitani, W., Huang, C., Narayanan, K., Lokugamage, K. G. & Makino, S. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat. Struct. Mol. Biol. 16, 1134\u20131140 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"34571_CR22","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1128\/JVI.01352-15","volume":"89","author":"KG Lokugamage","year":"2015","unstructured":"Lokugamage, K. G. et al. Middle east respiratory syndrome coronavirus nsp1 inhibits host gene expression by selectively targeting mRNAs transcribed in the nucleus while sparing mRNAs of cytoplasmic origin. J. Virol. 89, 10970\u201310981 (2015).","journal-title":"J. Virol."},{"key":"34571_CR23","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/S2666-5247(21)00027-6","volume":"2","author":"S Schroeder","year":"2021","unstructured":"Schroeder, S. et al. Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics. Lancet Microbe 2, e210\u2013e218 (2021).","journal-title":"Lancet Microbe"},{"key":"34571_CR24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.molcel.2020.10.034","volume":"80","author":"S Yuan","year":"2020","unstructured":"Yuan, S. et al. Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA. Mol. Cell 80, 1055\u20131066 e1056 (2020).","journal-title":"Mol. Cell"},{"key":"34571_CR25","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0140-6736(20)31757-8","volume":"396","author":"BE Young","year":"2020","unstructured":"Young, B. E. et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet 396, 603\u2013611 (2020).","journal-title":"Lancet"},{"key":"34571_CR26","doi-asserted-by":"publisher","unstructured":"Liu, S. et al. The PRRA insert at the S1\/S2 site modulates cellular tropism of SARS-CoV-2 and ACE2 usage by the closely related Bat RaTG13. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01751-20 (2021).","DOI":"10.1128\/JVI.01751-20"},{"key":"34571_CR27","doi-asserted-by":"publisher","unstructured":"Liu, S., Chou, C. K., Wu, W. W., Luan, B. & Wang, T. T. Stable cell clones harboring self-replicating SARS-CoV-2 RNAs for drug screen. J. Virol. https:\/\/doi.org\/10.1128\/jvi.02216-21 (2022).","DOI":"10.1128\/jvi.02216-21"},{"key":"34571_CR28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"34571_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19891-7","volume":"11","author":"FS Oladunni","year":"2020","unstructured":"Oladunni, F. S. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 11, 6122 (2020).","journal-title":"Nat. Commun."},{"key":"34571_CR30","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1080\/22221751.2020.1838955","volume":"9","author":"R Rathnasinghe","year":"2020","unstructured":"Rathnasinghe, R. et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg. Microbes Infect. 9, 2433\u20132445 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"34571_CR31","doi-asserted-by":"publisher","unstructured":"Golden, J. W. et al. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight 5, https:\/\/doi.org\/10.1172\/jci.insight.142032 (2020).","DOI":"10.1172\/jci.insight.142032"},{"key":"34571_CR32","doi-asserted-by":"crossref","unstructured":"Yinda, C. K. et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog 17, e1009195 (2021).","DOI":"10.1371\/journal.ppat.1009195"},{"key":"34571_CR33","doi-asserted-by":"crossref","unstructured":"Rathnasinghe, R. et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect 9, 2433\u20132445 (2020).","DOI":"10.1080\/22221751.2020.1838955"},{"key":"34571_CR34","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020).","journal-title":"Nature"},{"key":"34571_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"34571_CR36","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/cid\/ciaa644","volume":"71","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428\u20132446 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"34571_CR37","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"34571_CR38","doi-asserted-by":"publisher","unstructured":"Selvaraj, P. et al. SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters. Life Sci. Alliance 4, https:\/\/doi.org\/10.26508\/lsa.202000886 (2021).","DOI":"10.26508\/lsa.202000886"},{"key":"34571_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.virol.2017.11.012","volume":"517","author":"K Shirato","year":"2018","unstructured":"Shirato, K., Kawase, M. & Matsuyama, S. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology 517, 9\u201315 (2018).","journal-title":"Virology"},{"key":"34571_CR40","doi-asserted-by":"publisher","unstructured":"Bestle, D. et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance 3, https:\/\/doi.org\/10.26508\/lsa.202000786 (2020).","DOI":"10.26508\/lsa.202000786"},{"key":"34571_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"34571_CR42","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","volume":"585","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature 585, 588\u2013590 (2020).","journal-title":"Nature"},{"key":"34571_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 e278 (2020).","journal-title":"Cell"},{"key":"34571_CR44","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727\u201311734 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"34571_CR45","doi-asserted-by":"publisher","first-page":"e3001265","DOI":"10.1371\/journal.pbio.3001265","volume":"19","author":"AS Heffron","year":"2021","unstructured":"Heffron, A. S. et al. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol. 19, e3001265 (2021).","journal-title":"PLoS Biol."},{"key":"34571_CR46","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41590-021-01028-7","volume":"22","author":"N Smith","year":"2021","unstructured":"Smith, N. et al. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nat. Immunol. 22, 1428\u20131439 (2021).","journal-title":"Nat. Immunol."},{"key":"34571_CR47","doi-asserted-by":"publisher","first-page":"103788","DOI":"10.1016\/j.ebiom.2021.103788","volume":"75","author":"L Azzi","year":"2022","unstructured":"Azzi, L. et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine 75, 103788 (2022).","journal-title":"EBioMedicine"},{"key":"34571_CR48","doi-asserted-by":"publisher","unstructured":"King, R. G. et al. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge. Vaccines 9, https:\/\/doi.org\/10.3390\/vaccines9080881 (2021).","DOI":"10.3390\/vaccines9080881"},{"key":"34571_CR49","doi-asserted-by":"publisher","first-page":"103841","DOI":"10.1016\/j.ebiom.2022.103841","volume":"76","author":"A Alu","year":"2022","unstructured":"Alu, A. et al. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine 76, 103841 (2022).","journal-title":"EBioMedicine"},{"key":"34571_CR50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184 e113 (2020).","journal-title":"Cell"},{"key":"34571_CR51","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","volume":"185","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847\u2013859 e811 (2022).","journal-title":"Cell"},{"key":"34571_CR52","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","volume":"603","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 603, 493\u2013496 (2022).","journal-title":"Nature"},{"key":"34571_CR53","doi-asserted-by":"publisher","unstructured":"Stauft, C. B., Selvaraj, P., Lien, C. Z., Starost, M. F. & Wang, T. T. Long-term immunity in convalescent Syrian hamsters provides protection against new-variant SARS-CoV-2 infection of the lower but not upper respiratory tract. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.27641 (2022).","DOI":"10.1002\/jmv.27641"},{"key":"34571_CR54","doi-asserted-by":"publisher","first-page":"eabj2641","DOI":"10.1126\/scitranslmed.abj2641","volume":"13","author":"A Chandrashekar","year":"2021","unstructured":"Chandrashekar, A. et al. Prior infection with SARS-CoV-2 WA1\/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. Sci. Transl. Med. 13, eabj2641 (2021).","journal-title":"Sci. Transl. Med."},{"key":"34571_CR55","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.abc5343","volume":"369","author":"W Deng","year":"2020","unstructured":"Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369, 818\u2013823 (2020).","journal-title":"Science"},{"key":"34571_CR56","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1126\/science.abc4776","volume":"369","author":"A Chandrashekar","year":"2020","unstructured":"Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812\u2013817 (2020).","journal-title":"Science"},{"key":"34571_CR57","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848 e843 (2020).","journal-title":"Cell Host Microbe"},{"key":"34571_CR58","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41596-021-00491-8","volume":"16","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Engineering SARS-CoV-2 using a reverse genetic system. Nat. Protoc. 16, 1761\u20131784 (2021).","journal-title":"Nat. Protoc."},{"key":"34571_CR59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.virol.2021.01.005","volume":"556","author":"CB Stauft","year":"2021","unstructured":"Stauft, C. B., Lien, C. Z., Selvaraj, P., Liu, S. & Wang, T. T. The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters. Virology 556, 96\u2013100 (2021).","journal-title":"Virology"},{"key":"34571_CR60","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"34571_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00410-8","volume":"6","author":"CA Meseda","year":"2021","unstructured":"Meseda, C. A. et al. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge. NPJ Vaccines 6, 145 (2021).","journal-title":"NPJ Vaccines"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34571-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34571-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34571-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T11:03:01Z","timestamp":1668250981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34571-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["34571"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-34571-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"10 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L., C.B.S, P.S., C.Z.L., and T.T.W. are inventors on a patent filed by the U.S. FDA based on the results described in this manuscript. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6792"}}